Funding for this research was provided by:
Received: 20 December 2021
Accepted: 15 April 2022
First Online: 4 May 2022
: Study documents, including the protocol, demographic and health information form, interview guide, screener, informed consent form, and SE-C19, received ethical approval from the New England Independent Review Board (study number: 1291666) prior to any contact with patients. All patients were ≥ 18 years and completed and provided an e-signature in an electronic informed consent form before the interview, and provided verbal consent at the start of the interview.
: Not applicable.
: DR is a Regeneron Pharmaceuticals, Inc. employee/stockholder and former Roche employee, and current stockholder. JI and VM are Regeneron Pharmaceuticals, Inc. employees/stockholders. NM, AR, and KP are employees of Modus Outcomes and consulted for Regeneron Pharmaceuticals, Inc. SS is an Excision BioTherapeutics employee/stockholder and former Regeneron Pharmaceuticals, Inc. employee, and current stockholder. AP has received consulting fees from Regeneron Pharmaceuticals, Inc. and honoraria from NACE (CME) and has participated in an advisory board for Boehringer Ingelheim.